NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular ...

NeoGenomics, Inc. recently announced that its PanTracer LBx liquid biopsy test has received Medicare coverage under the MolDX Plasma-Based Genomic Profiling in Solid Tumors policy, allowing eligible ...

NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, NeoGenomics officially launched RaDaR ST, a tumor-informed circulating tumor ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, marking nine consecutive quarters of double-digit growth. He also announced his retirement effective ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth ...

Customer satisfaction remained a standout, with a Net Promoter Score of 79 and further improvement in 2025, indicating deep loyalty among clinicians. The number of pathologists and oncologists ...

Southwest Florida companies Hertz, Herc, NeoGenomics, and Alico report Q4 and full-year 2025 earnings, showing mixed results.

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a ...

FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today ...